July 18, 2026 · Decision research
Biotech Pharma Breakthroughs
Finding
The consensus framing that the oral GLP-1 catalyst expands TAM is wrong on the dominant metric; ~64% of Wegovy pill prescriptions are switches from injectable GLP-1s, not new patients, and the unit price has collapsed 70-85% to defend volume. The TAM is being redistributed at lower price points, not enlarged.
What changed
(1) Truveta real-world data (Feb 2026) shows only ~36% of Wegovy pill users are net-new to GLP-1 therapy; the rest cannibalize injectable scripts. (2) IQVIA pushed its $130B peak from 2028 to 2034 -- a 6-year delay. (3) Jefferies cut peak TAM to ~$80B (from >$100B); Goldman cut its 2030 TAM to $105B (from $130B, -19%). (4) Lilly cut orforglipron (Foundayo) self-pay to $149-$399, with $50 Medicare access from July 1, 2026 -- an effective ~70-85% price cut vs. the ~$1,000 Zepbound WAC. (5) CVS Caremark removed Zepbound from formulary in favor of Wegovy -- a payer consolidation signal, not catego
Decision
Move from neutral/wait to **HEDGE the GLP-1 complex**. Underweight pure-play Novo Nordisk (NVO); trim long Eli Lilly (LLY) exposure; prefer diversified pharma with non-obesity growth (MRK, PFE, AZN, ROG) over GLP-1 specialists. Rationale: with ~64% cannibalization and 70-85% price compression, revenue-per-script is collapsing faster than script volume is growing. Even bullish script-count trajectories cannot recover the unit-economics gap. Net revenue per script is the right metric; script count alone is vanity.
Watch next
(1) Q2 2026 earnings (NVO Jul 30; LLY Aug 7) for net realized price per script; if average net price falls below $400, the bull case is broken. (2) Truveta Q3 switch-rate update -- if the 64% switch share rises, Zepbound franchise erosion is accelerating. (3) 12-month real-world persistence from any large claims database; a print >45% repairs the LTV math, <30% confirms revenue leakage. (4) CMS GLP-1 bridge enrollment in Q3 2026; <100k enrollees undermines the volume-defense narrative. (5) CVS Caremark formulary decisions at Express Scripts and OptumRx -- a second PBM favoring Wegovy would har